Virios Therapeutics (VIRI) Competitors $6.76 +0.07 (+1.05%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. RAPT, DRUG, KRRO, ATXS, DSGN, ALMS, KMDA, EOLS, MLTX, and FDMTShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Rapt Therapeutics (RAPT), Bright Minds Biosciences (DRUG), Korro Bio (KRRO), Astria Therapeutics (ATXS), Design Therapeutics (DSGN), Alumis (ALMS), Kamada (KMDA), Evolus (EOLS), MoonLake Immunotherapeutics (MLTX), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Rapt Therapeutics Bright Minds Biosciences Korro Bio Astria Therapeutics Design Therapeutics Alumis Kamada Evolus MoonLake Immunotherapeutics 4D Molecular Therapeutics Virios Therapeutics (NASDAQ:VIRI) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Do analysts recommend VIRI or RAPT? Rapt Therapeutics has a consensus price target of $23.50, suggesting a potential downside of 20.18%. Given Rapt Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapt Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rapt Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.55 Is VIRI or RAPT more profitable? Rapt Therapeutics' return on equity of -67.92% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Rapt Therapeutics N/A -67.92%-59.59% Which has higher earnings & valuation, VIRI or RAPT? Virios Therapeutics has higher earnings, but lower revenue than Rapt Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-25.04Rapt Therapeutics$1.53M318.26-$129.87M-$14.17-2.08 Which has more risk and volatility, VIRI or RAPT? Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Does the media favor VIRI or RAPT? In the previous week, Rapt Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Rapt Therapeutics and 0 mentions for Virios Therapeutics. Rapt Therapeutics' average media sentiment score of 0.33 beat Virios Therapeutics' score of 0.00 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Rapt Therapeutics Neutral Do institutionals & insiders hold more shares of VIRI or RAPT? 9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 2.4% of Rapt Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryRapt Therapeutics beats Virios Therapeutics on 11 of the 15 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.18M$1.05B$6.11B$10.56BDividend YieldN/A4.84%5.69%4.75%P/E Ratio-25.041.2685.4827.60Price / SalesN/A28.98616.90236.99Price / CashN/A17.6437.9261.55Price / Book33.807.5213.136.76Net Income-$5.30M-$7.77M$3.30B$275.88M7 Day Performance-4.38%26.65%4.29%2.81%1 Month Performance37.96%27.90%9.45%9.24%1 Year Performance138.87%-5.67%86.64%35.42% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$6.76+1.0%N/A+4,261.3%$130.18MN/A-25.045RAPTRapt Therapeutics3.5013 of 5 stars$25.25-5.2%$23.50-6.9%+95.7%$423.76M$1.53M-1.8180Analyst ForecastDRUGBright Minds Biosciences3.0523 of 5 stars$59.53+3.6%$81.00+36.1%+5,011.1%$421.96MN/A-64.41N/APositive NewsKRROKorro Bio2.194 of 5 stars$44.56+4.1%$86.83+94.9%+30.8%$420.63M$2.27M-4.5970ATXSAstria Therapeutics2.6039 of 5 stars$7.34-0.3%$30.20+311.7%-25.1%$414.27MN/A-3.6530News CoverageAnalyst ForecastGap UpDSGNDesign Therapeutics0.0487 of 5 stars$7.05+2.8%N/A+41.1%$401.21MN/A-6.2940Positive NewsAnalyst ForecastALMSAlumis3.4444 of 5 stars$3.82-3.2%$20.17+427.4%-57.1%$399.07MN/A0.00N/ANews CoverageAnalyst ForecastKMDAKamada4.5336 of 5 stars$6.92+0.7%$13.00+88.0%+30.0%$397.71M$169.52M20.34360Positive NewsAnalyst ForecastAnalyst RevisionEOLSEvolus3.9663 of 5 stars$6.13-0.2%$21.25+246.7%-62.4%$396.62M$266.27M-6.26170Positive NewsMLTXMoonLake Immunotherapeutics2.9357 of 5 stars$6.16-1.5%$43.82+611.9%-81.7%$395.02MN/A-2.212Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeFDMT4D Molecular Therapeutics2.2817 of 5 stars$8.41+0.7%$30.40+261.4%+3.0%$393.12M$40K-2.38120Analyst Forecast Related Companies and Tools Related Companies Rapt Therapeutics Alternatives Bright Minds Biosciences Alternatives Korro Bio Alternatives Astria Therapeutics Alternatives Design Therapeutics Alternatives Alumis Alternatives Kamada Alternatives Evolus Alternatives MoonLake Immunotherapeutics Alternatives 4D Molecular Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
